- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07489495
Klinická studie belzutifanu (MK-6482) a zanzalintinibu u pacientů s renálním karcinomem (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Fáze 3, randomizovaná, dvojitě zaslepená studie belzutifanu + zanzalintinibu versus belzutifan + placebo u pacientů s pokročilým RCC, u kterých došlo k progresi během nebo po léčbě PD-1/L1 a VEGF-TKI v sekvenci nebo v kombinaci (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Toll Free Number
- Telefonní číslo: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studijní místa
-
-
-
CABA, Argentina, C1426ANZ
- Nábor
- Instituto Alexander Fleming ( Site 0252)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +541132218900
-
La Rioja, Argentina, X5004BAL
- Nábor
- Centro Oncológico Riojano Integral ( Site 0256)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +543804436443X108
-
San Juan, Argentina, J5402BGA
- Nábor
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +54 2644229585
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1426AHB
- Nábor
- Centro Oncologico Korben ( Site 0254)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +541159507952
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1181
- Nábor
- Hospital Italiano de Buenos Aires ( Site 0253)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +541149590200
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Nábor
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +542234963224
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, X5800ALB
- Nábor
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +543584620273
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Nábor
- Sanatorio Parque ( Site 0251)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +5493416955611
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Nábor
- Instituto de Oncología de Rosario ( Site 0257)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +543414484830
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Austrálie, 2109
- Pozastaveno
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba, Queensland, Austrálie, 4102
- Pozastaveno
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3000
- Pozastaveno
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch, Western Australia, Austrálie, 6150
- Pozastaveno
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazílie, 29055-450
- Nábor
- CEDOES ( Site 0303)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +552721250202
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 80510-130
- Nábor
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazílie, 59062-000
- Nábor
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazílie, 14026-610
- Nábor
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +55 16 3913-8181
-
São José do Rio Preto, São Paulo, Brazílie, 15090-000
- Nábor
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +55 17 3201-5054
-
-
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chile, 1720430
- Nábor
- IC La Serena Research ( Site 0405)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 56958646664
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5500243
- Nábor
- Clínica Puerto Montt ( Site 0404)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +56985383586
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- Nábor
- Fundacion Arturo Lopez Perez ( Site 0401)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Nábor
- Bradfordhill ( Site 0400)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 56229490970
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Nábor
- ONCOCENTRO APYS ( Site 0403)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 56323320850
-
-
-
-
Capital Region
-
Herlev, Capital Region, Dánsko, 2730
- Nábor
- Herlev Hospital ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 00 45 38689191
-
-
Central Jutland
-
Aarhus, Central Jutland, Dánsko, 8200
- Nábor
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4591167472
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Dánsko, 5000
- Nábor
- Odense Universitets Hospital ( Site 1000)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4566113333
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Francie, 06189
- Nábor
- Centre Antoine Lacassagne ( Site 1209)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33492031538
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Francie, 13003
- Nábor
- Hopital Europeen Marseille ( Site 1216)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33413427427
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Francie, 31059
- Nábor
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33531155050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, Francie, 49933
- Nábor
- CHU Angers ( Site 1204)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33241354694
-
-
Pays de la Loire Region
-
Le Mans, Pays de la Loire Region, Francie, 72000
- Nábor
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33 243297908
-
Saint Priest En Jarez, Pays de la Loire Region, Francie, 42271
- Nábor
- CHU de Saint-Etienne ( Site 1202)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33477917082
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Francie, 94800
- Nábor
- Gustave Roussy ( Site 1214)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +33142114211
-
-
-
-
Limburg
-
Maastricht, Limburg, Holandsko, 6229 HX
- Nábor
- Maastricht UMC+ ( Site 1901)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +31433877025
-
-
North Holland
-
Amsterdam, North Holland, Holandsko, 1066 CX
- Nábor
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +3120 512 9111
-
-
South Holland
-
Schiedam, South Holland, Holandsko, 3118 JH
- Nábor
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +31108931441
-
The Hague, South Holland, Holandsko, 2545 AA
- Nábor
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +3170 210 2143
-
-
-
-
-
Bari, Itálie, 70124
- Nábor
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 00390805593767
-
Bologna, Itálie, 40138
- Nábor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +390512142204
-
Milan, Itálie, 20133
- Nábor
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 02 2390 3028
-
Perugia, Itálie, 06132
- Nábor
- AO Santa Maria della Misericordia ( Site 1805)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +39 0755784188
-
Roma, Itálie, 00168
- Nábor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 00390630155202
-
Roma, Itálie, 00144
- Nábor
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +39 0652666919
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Itálie, 47014
- Nábor
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +390543739100
-
-
Milano
-
Rozzano, Milano, Itálie, 20089
- Nábor
- Istituto Clinico Humanitas ( Site 1808)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 0282244061
-
-
Treviso
-
Castelfranco Veneto, Treviso, Itálie, 31033
- Nábor
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +39 0423732336
-
-
Tuscany
-
Florence, Tuscany, Itálie, 50134
- Nábor
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +390557949648
-
-
-
-
-
Haifa, Izrael, 3109601
- Nábor
- Rambam Health Care Campus ( Site 1600)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +97247772688
-
Kfar Saba, Izrael, 4428164
- Nábor
- Meir Medical Center. ( Site 1603)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +97297472555
-
Petah Tikva, Izrael, 4941492
- Nábor
- Rabin Medical Center ( Site 1602)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 97239378074
-
Ramat Gan, Izrael, 5265601
- Nábor
- Sheba Medical Center ( Site 1601)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 97235303030
-
-
-
-
-
Seoul, Jižní Korea, 05505
- Nábor
- Asan Medical Center ( Site 2901)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82-2-3010-5977
-
Seoul, Jižní Korea, 06351
- Nábor
- Samsung Medical Center ( Site 2902)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82-2-3410-1767
-
Seoul, Jižní Korea, 03722
- Nábor
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82-2-2228-8138
-
-
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Nábor
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 613-737-7700
-
-
Quebec
-
Québec, Quebec, Kanada, G1J 1Z4
- Nábor
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 418-525-4444
-
-
-
-
-
Berlin, Německo, 10117
- Nábor
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4930450515288
-
-
Bavaria
-
Augsburg, Bavaria, Německo, 86156
- Nábor
- Universitaetsklinikum Augsburg ( Site 1316)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +498214002348
-
Munich, Bavaria, Německo, 81675
- Nábor
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 00498941402522
-
-
Thuringia
-
Jena, Thuringia, Německo, 07747
- Nábor
- Universitätsklinikum Jena ( Site 1313)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4936419329970
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polsko, 60-185
- Nábor
- AIDPORT Sp. z o.o. ( Site 2118)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48570783100
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polsko, 30-727
- Nábor
- Pratia MCM Krakow ( Site 2115)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48122958160
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polsko, 08-110
- Nábor
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48256403300
-
Warsaw, Masovian Voivodeship, Polsko, 02-172
- Nábor
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48225725959
-
Warsaw, Masovian Voivodeship, Polsko, 02-781
- Nábor
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48225462331
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polsko, 44-102
- Nábor
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +48322788237
-
-
-
-
-
Birmingham, Spojené království, B15 2GW
- Nábor
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4407789651543
-
Cardiff, Spojené království, CF14 2TL
- Nábor
- Velindre Cancer Centre ( Site 2612)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +442920615888
-
Southampton, Spojené království, SO16 6YD
- Nábor
- University Hospital of Southampton ( Site 2606)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 023 8077 7222
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Spojené království, CB2 0QQ
- Nábor
- Addenbrookes Hospital ( Site 2605)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +441223805000
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Spojené království, EH4 2XU
- Nábor
- Western General Hospital ( Site 2608)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +441315371398
-
-
Glasgow City
-
Glasgow, Glasgow City, Spojené království, G12 0YN
- Nábor
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +441413019916
-
-
Leicestershire
-
Leicester, Leicestershire, Spojené království, LE1 5WW
- Nábor
- Leicester Royal Infirmary ( Site 2604)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 0300 303 1573
-
-
London, City of
-
Northwood, London, City of, Spojené království, HA6 2RN
- Nábor
- Mount Vernon Hospital ( Site 2607)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +4401923826111
-
-
Manchester
-
Withington, Manchester, Spojené království, M20 4BX
- Nábor
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 0161 918 2546
-
-
-
-
California
-
Duarte, California, Spojené státy, 91010
- Nábor
- City of Hope Comprehensive Cancer Center ( Site 0129)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 877-817-9982
-
Irvine, California, Spojené státy, 92618
- Nábor
- City of Hope Lennar Foundation Cancer Center ( Site 0142)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: see site 0129
-
-
Georgia
-
Marietta, Georgia, Spojené státy, 30060
- Nábor
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 770-281-5124
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- Nábor
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 502-562-4673
-
Louisville, Kentucky, Spojené státy, 40207
- Nábor
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 502-899-3366
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Beth Israel Deaconess Medical Center ( Site 0139)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 617-667-7000
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Dana Farber Cancer Institute ( Site 0135)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 617-632-3000
-
-
Michigan
-
Grand Rapids, Michigan, Spojené státy, 49503
- Nábor
- The Cancer and Hematology Centers ( Site 0123)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 616-954-9800
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- Nábor
- Washington University School of Medicine ( Site 0114)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 314-362-7355
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Nábor
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 551-996-5900
-
Morristown, New Jersey, Spojené státy, 07960
- Nábor
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 973-971-7960
-
-
New York
-
New York, New York, Spojené státy, 10065
- Nábor
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 347-798-9213
-
-
Tennessee
-
Germantown, Tennessee, Spojené státy, 38138
- Nábor
- The West Clinic, P.C. ( Site 0115)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 901-683-0055
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- Nábor
- UT Southwestern Medical Center ( Site 0119)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 214-648-3111
-
-
-
-
-
Adana, Turecko (Türkiye), 01140
- Nábor
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +905372688986
-
Ankara, Turecko (Türkiye), 06620
- Nábor
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +90 312 595 71 12
-
Edirne, Turecko (Türkiye), 22030
- Nábor
- Trakya University Medical Faculty Hospital ( Site 2502)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +9005378528123
-
Istanbul, Turecko (Türkiye), 34010
- Nábor
- Koc Universitesi Hastanesi ( Site 2501)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 0090 850 250 8 250
-
Izmir, Turecko (Türkiye), 35080
- Nábor
- Ege Universitesi Hastanesi ( Site 2503)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 0 232 343 43 43
-
-
Ankara
-
Sıhhiye, Ankara, Turecko (Türkiye), 06230
- Nábor
- Hacettepe Universite Hastaneleri ( Site 2500)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +905439340493
-
-
-
-
-
Hradec Králové, Česko, 500 05
- Nábor
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420727854666
-
Olomouc, Česko, 779 00
- Nábor
- Fakultni nemocnice Olomouc ( Site 0901)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420588445923
-
Prague, Česko, 150 06
- Nábor
- Fakultni nemocnice v Motole ( Site 0900)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420734236410
-
Prague, Česko, 128 08
- Nábor
- Fakulti poliklinika ( Site 0906)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420224966405
-
-
Brno-mesto
-
Brno, Brno-mesto, Česko, 656 53
- Nábor
- Masarykuv onkologicky ustav ( Site 0903)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420543132216
-
-
Ostrava Mesto
-
Ostrava, Ostrava Mesto, Česko, 708 52
- Nábor
- Fakultni nemocnice Ostrava ( Site 0904)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +420597374322
-
-
-
-
Attica
-
Athens, Attica, Řecko, 185 47
- Nábor
- Metropolitan Hospital ( Site 1402)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +302104809667
-
Athens, Attica, Řecko, 124 62
- Nábor
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +302105832549
-
Athens, Attica, Řecko, 115 28
- Nábor
- Alexandra General Hospital of Athens ( Site 1400)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +302132162543
-
-
-
-
-
Barcelona, Španělsko, 08035
- Nábor
- Hospital Universitari Vall d Hebron ( Site 2303)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34934894350
-
Las Palmas, Španělsko, 35016
- Nábor
- Hospital Insular de Gran Canaria ( Site 2308)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34928441738
-
Madrid, Španělsko, 28041
- Nábor
- Hospital Universitario 12 de Octubre ( Site 2300)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34913908339
-
Valencia, Španělsko, 46009
- Nábor
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34961114229
-
-
Andalusia
-
Seville, Andalusia, Španělsko, 41013
- Nábor
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Španělsko, 08908
- Nábor
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34932607744
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Španělsko, 28007
- Nábor
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34914269393
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
Ostatní jména:
Tablet for oral administration.
Ostatní jména:
|
|
Aktivní komparátor: Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
Ostatní jména:
Zanzalintinib-matching placebo tablet for oral administration. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free Survival (PFS)
Časové okno: Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
Časové okno: Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Objective Response Rate (ORR)
Časové okno: Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
Časové okno: Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Časové okno: Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Časové okno: Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Časové okno: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Časové okno: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Časové okno: Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
Časové okno: Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Časové okno: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Časové okno: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
Časové okno: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
Časové okno: Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Medical Director, Merck Sharp & Dohme LLC
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Novotvary podle histologického typu
- Novotvary, žlázové a epiteliální
- Adenokarcinom
- Urologické novotvary
- Karcinom
- Novotvary ledvin
- Karcinom, renální buňka
- Belzutifan
Další identifikační čísla studie
- 6482-034
- U1111-1311-4692 (Identifikátor registru: UTN)
- 2024-516993-31-00 (Identifikátor registru: EU CT)
- LITESPARK-034 (Jiný identifikátor: MSD)
- MK-6482-034 (Jiný identifikátor: MSD)
- LS-034 (Jiný identifikátor: MSD)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .